MCL Literature Feed

This case report documents a rare presentation of mantle cell lymphoma as complete heart block from cardiac metastasis, highlighting a critical differential diagnosis for unexplained conduction abnormalities.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

A rare case of MCL presenting as diffuse polyposis throughout the entire GI tract achieved complete response after R-CHOP followed by salvage chemotherapy plus ibrutinib, highlighting this unusual presentation.

This case report details a rare MCL presentation as intestinal intussusception, requiring surgical resection for diagnosis and initial management prior to systemic chemotherapy in a young patient.

Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.

This preclinical study identifies PLK-1 gene methylation as a key driver of bendamustine resistance, which was reversible with demethylating agents, suggesting a potential new therapeutic strategy.

This case links progressive necrotizing xanthogranuloma, a rare paraneoplastic syndrome, as the presenting sign of MCL, underscoring the need for hematologic workup for specific skin/ocular findings.

This preclinical study identifies SOX11 as an endogenous inhibitor of SAMHD1, which sensitizes mantle cell lymphoma to cytarabine, suggesting SOX11 status as a predictive biomarker for chemotherapy efficacy.

This preclinical study identifies that SOX11 upregulates the antioxidant PRDX2, promoting chemoresistance in aggressive MCL, and suggests PRDX2 as a novel therapeutic target to overcome drug resistance.

A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.

This case report describes the rare Warburg effect (severe hypoglycemia, lactic acidosis) in an MCL patient, highlighting its potential for cardiac toxicity and the utility of hemodialysis for stabilization.

This large retrospective study of orbital lymphomas identifies mantle cell lymphoma as a rare subtype but provides no specific clinical or prognostic data for this particular presentation.

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.

This retrospective study of 134 patients demonstrates that adding a BTK inhibitor to chemotherapy improves efficacy and prolongs progression-free survival in relapsed/refractory MCL.

Preclinically, chlorambucil and ibrutinib show synergistic apoptosis in an MCL cell line, suggesting a novel chemo-BTKi combination strategy potentially mediated by inhibiting the AKT signaling pathway.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.

This retrospective review of 14 Moroccan patients describes real-world MCL clinical features and treatment patterns, providing rare epidemiological data from North Africa.

A rare case of extranodal composite MCL and classical Hodgkin lymphoma highlights the need for comprehensive pathological workup to identify dual pathologies, which impacts treatment and relapse patterns.

This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.

This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.